Compugen Ltd. (CGEN) Q1 2025 Earnings Call Transcript
Compugen Ltd. (NASDAQ:CGEN ) Q1 2025 Earnings Conference Call May 19, 2025 8:30 AM ET Company Participants Yvonne Naughton - VP, Head of IR & Corporate Communications Anat Cohen-Dayag - President & CEO David Silberman - CFO Michelle Mahler - Chief Medical Officer Eran Ophir - Chief Scientific Officer Conference Call Participants Daina Graybosch - Leerink Partners Rohan Mathur - Oppenheimer Asthika Goonewardene - Truist Operator Ladies and gentlemen, thank you for joining us today.
Compugen Ltd. (CGEN) Q4 2024 Earnings Call Transcript
Compugen Ltd. (NASDAQ:CGEN ) Q4 2024 - Earnings Conference Call March 4, 2025 8:30 AM ET Company Participants Yvonne Naughton - VP, Head of IR and Corporate Communications Anat Cohen-Dayag - President and CEO David Silberman - CFO Michelle Mahler - Chief Medical Officer Eran Ophir - Chief Scientific Officer Conference Call Participants Karina Rabayeva – Truist Securities Daina Graybosch - Leerink Partners Leland Gershell - Oppenheimer Tony Butler - Rodman and Renshaw Stephen Willey - Stifel Operator Ladies and gentlemen, thank you for joining us today.
Compugen (CGEN) Reports Q4 Loss, Misses Revenue Estimates
Compugen (CGEN) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of $0.07. This compares to earnings of $0.11 per share a year ago.
Compugen: Immuno-Oncology Innovator Poised For A Comeback
Compugen's innovative approach targets under-explored immune pathways like PVRIG and IL-18 binding protein, offering potential upside, despite current market skepticism. With $113.2 million in cash and milestone payments from Gilead and AstraZeneca, Compugen has a solid financial runway extending into 2027. Compugen's pipeline, including COM701 and COM503, aims to transform tumor responsiveness through unique immunotherapy strategies, potentially reshaping the immuno-oncology landscape.
Compugen initiated with bullish view at Oppenheimer, here's why
Compugen +0.05 (+3.14%) AstraZeneca +0.44 (+0.66%) Gilead +0.7 (+0.79%)
Compugen Ltd. (CGEN) Q3 2024 Earnings Call Transcript
Start Time: 08:30 January 1, 0000 9:30 AM ET Compugen Ltd. (NASDAQ:CGEN ) Q3 2024 Earnings Call November 12, 2024, 08:30 AM ET Company Participants Anat Cohen-Dayag - President and CEO David Silberman - CFO Michelle Mahler - Chief Medical Officer Eran Ophir - Chief Scientific Officer Oladapo Yeku - Assistant Professor of Medicine, Harvard Medical School, and Director of Translational Research, Gynecologic Oncology Program Yvonne Naughton - Head of IR and Corporate Communications Conference Call Participants Stephen Willey - Stifel Daina Graybosch - Leerink Partners Tony Butler - Rodman and Renshaw Asthika Goonewardene - Truist Securities Operator Ladies and gentlemen, thank you for joining us today.
Compugen (CGEN) Q3 Earnings and Revenues Lag Estimates
Compugen (CGEN) came out with quarterly earnings of $0.01 per share, missing the Zacks Consensus Estimate of $0.06 per share. This compares to loss of $0.11 per share a year ago.
Compugen Gears Up to Report Q3 Earnings: Here's What to Expect
On CGEN's third-quarter 2024 earnings call, investors' focus is likely to be on updates on its pipeline candidates being studied for cancer immunotherapies.
Compugen (CGEN) Upgraded to Strong Buy: What Does It Mean for the Stock?
Compugen (CGEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Can Compugen (CGEN) Run Higher on Rising Earnings Estimates?
Compugen (CGEN) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Compugen Ltd. (CGEN) Q2 2024 Earnings Call Transcript
Compugen Ltd. (NASDAQ:CGEN ) Q2 2024 Earnings Conference Call August 6, 2024 8:30 AM ET Company Participants Yvonne Naughton - Head of Investor Relations and Corporate Communications Anat Cohen-Dayag - President and Chief Executive Officer Alberto Sessa - Chief Financial Officer Michelle Mahler - Chief Medical Officer Eran Ophir - Chief Scientific Officer Conference Call Participants Stephen Willey - Stifel Asthika Goonewardene - Truist Securities Daina Graybosch - Leerink Partners Tony Butler - Rodman & Renshaw Operator Ladies and gentlemen, thank you for joining us today.
Compugen (CGEN) Reports Q2 Loss, Tops Revenue Estimates
Compugen (CGEN) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to loss of $0.11 per share a year ago.
